Redhill Biopharma Ltd - ADR (NASDAQ:RDHL) jumped briefly this morning before dipping into the red recently in the U.S. pre-market session on Monday after the U.S. FDA granted a Qualified Infectious Disease Product (QIDP) fast-track designation to its Phase III Helicobacter pylori (H. pylori) eradication therapy, RHB-105. The granted QIDP designation allows the Israeli biopharmaceutical company to benefit from Fast-Track development status with an expedited development pathway for RHB-105 and "priority review" status. The priority review status provides for a shorter review time by the FDA of a future potential marketing application. If approved, RHB-105 will also receive an additional five years of U.S. market exclusivity on top of the standard exclusivity period. Redhill Biopharma Ltd - ADR (NASDAQ:RDHL) closed down to $8.80 on Friday, in a 52-week range of $8.37 - $21.Click here for a free comprehensive Trend Analysis ReportOrexigen Therapeutics, Inc. (NASDAQ:OREX) Monday said it ended Q3 2014 with a net profit of $11.3 million, or $0.09 per share, after revenues increased to $30.9 million and operating expenses fell to $17.8 million. The increase in revenues was due to recognition of two regulatory/development milestones, consisting of $20 million due upon regulatory approval in the U.S. and $10.0 million due upon the delivery of Contrave launch supplies to Takeda. In the same period last year, Orexigen Therapeutics, Inc. (NASDAQ:OREX) had a net loss of $18.6 million, or $0.19 per share, after generating revenues of only $0.9 million and spending $19.4 million in operating costs. Analysts were expecting a net loss of $0.15 per share, according to Capital IQ.Click here for a free comprehensive Trend Analysis ReportSunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced a Q3 loss wider than the loss reported a year ago as revenues decreased and fell short of Street projections. The company reported a Q3 loss per share of $0.25, wider than the loss of $0.16 reported a year ago and wider than the loss of $0.15 expected by analysts. Total revenues $0.85 million were down from $1.98 million in Q3 2013 and missed analyst projections of $1.99 million for the quarter.Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has announced the submission of a letter of intent to file a marketing authorization application for vosaroxin in relapsed or refractory AML with the European Medicines Agency (EMA). The drug is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Shares of SNSS are at $1.63 within a 52-week range of $1.00 - $8.46.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
